他们利用 CRISPR/Cas 介导的一体化方法，在符合药品生产质量管理规范（Good Manufacturing Practice，GMP）的平台上，将抗 EBV（gp350）的嵌合抗原受体（Chimeric Antigen Receptor，CAR）插入 T 细胞受体（T-cell receptor，TRAC）位点，同时敲除糖皮质激素受体（Glucocorticoid Receptor ...

Epstein-Barr virus (EBV), a member of the herpesvirus family, is a highly common human pathogen that can remain latent in B lymphocytes after the primary infection. Although this latent state is ...

Despite EBV’s potential to cause disease, there are few therapeutic options and no licensed vaccines targeting the virus.

On the other side, the anti-EBV nAbs mimic CR2, where they act as a lock to block the EBV gp350 protein from binding to a cell for the virus to infect. The mimicry existing on both sides of this ...

EBV infects 95% of people and doesn’t usually ... as well as an antigen derived from gp350. Most earlier vaccine attempts have targeted gp350 alone. In animal studies, a similar vaccine ...

Study: TGFβ links EBV to multisystem inflammatory syndrome in children. Image Credit: Kateryna Kon / Shutterstock A new study published in the journal Nature reveals a potential mechanism ...

In the lymph nodes of the neck of people with multiple sclerosis (MS), certain immune cells show abnormalities in activity and signs of reactions against the Epstein-Barr virus (EBV), a new study ...

The Wistar Institute's Paul M. Lieberman, Ph.D. and lab identified and tested a new method for targeting certain cancers caused by Epstein-Barr Virus (EBV), in the paper, "USP7 inhibitors ...